Drug Trial Radar · NCT05355207
Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Jan 2025
Study completion Jan 2025
Sponsor
- Lead sponsor
- Trellis Bioscience LLCIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis, thus making these bacteria substantially more susceptible to established antibiotic treatment regimens. This initial study is to assess overall safety and pharmacokinetics (PK) of TRL1068. The goal of the development program is to demonstrate effectiveness of TRL1068 in difficult to treat bacterial infections such as in CRS.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
TRL1068Drug
A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of abnormal physical exam findingsTime frame: 6 weeks
- Incidence of abnormal serum chemistries and hematologyTime frame: 6 weeks
- Incidence of abnormal vital signs (temperature)Time frame: 6 weeks
- Incidence of abnormal vital signs (blood pressure)Time frame: 6 weeks
- Incidence of abnormal vital signs (heart rate)Time frame: 6 weeks
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 7 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in serum (Cmax)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in serum (Cmin)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in serum (Tmax)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in serum (AUCLAST)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in serum (AUCINF)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Cmax)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Cmin)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Tmax)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (AUCLAST)Time frame: 6 weeks
- Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (AUCINF)Time frame: 6 weeks
- Characterize the pharmacodynamics (PD) of TRL1068 (time to resolution of bacterial pathogen infection)Time frame: 6 weeks
- Characterize the pharmacodynamics (PD) of TRL1068 (time to resolution of signs and symptoms of acute exacerbation)Time frame: 6 weeks
- Assess the immunogenicity of TRL1068 as measured by anti-drug antibodies (ADAs)Time frame: 6 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.